Last €38.38 EUR
Change Today 0.00 / 0.00%
Volume 0.0
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 10:31 AM 07/2/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
€38.38
Previous Close
€38.38
Day High
€38.38
Day Low
€38.38
52 Week High
02/21/14 - €41.60
52 Week Low
08/8/13 - €32.72
Market Cap
61.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
1.6B
EX-Date
07/11/14
P/E TM
--
Dividend
€1.66
Dividend Yield
3.13%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 07/25/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Fourth Quarter of 2014 and Confirms Earnings Guidance for the Year 2014

AbbVie Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net earnings of $1,098 million or $0.82 per diluted share excluding specified items on net sales of $4,926 million compared to net earnings of $1,068 million or $0.82 per diluted share excluding specified items on net sales of $4,692 million a year ago. Operating earnings were $1,515 million compared to $1,453 million a year ago. Earnings before income tax expense was $1,433 million compared to $1,368 million a year ago. Diluted earnings per share were $0.68 compared to $0.66 a year ago. Non-GAAP pre-tax earnings were $1,710 million compared to $1,698 million a year ago. Non-GAAP after tax earnings were $1,330 million or $0.82 per diluted share compared to $1,319 million or $0.82 per diluted share a year ago. Second-quarter sales growth was driven primarily by the continued strength of HUMIRA. For the six months period, the company reported net earnings of $2,078 million or $1.53 per diluted share excluding specified items on net sales of $9,489 million compared to net earnings of $2,036 million or $1.50 per diluted share excluding specified items on net sales of $9,021 million a year ago. Operating earnings were $2,866 million compared to $2,758 million a year ago. Earnings before income tax expense was $2,719 million compared to $2,607 million a year ago. Diluted earnings per share were $1.29 compared to $1.27 a year ago. Non-GAAP pre-tax earnings were $3,190 million compared to $3,105 million a year ago. Non-GAAP after tax earnings were $2,480 million or $1.53 per diluted share compared to $2,414 million or $1.50 per diluted share a year ago. Total company sales growth was also driven by strong growth from key products including Synthroid, Sevoflurane and Duodopa. Excluding the potential impact of the transaction with Shire, the company is confirming its recently-increased diluted earnings-per-share guidance for the full-year 2014 of $3.06 to $3.16 on an adjusted basis, or $2.69 to $2.79 on a GAAP basis. The company's 2014 outlook excludes any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy. The company's 2014 adjusted diluted earnings-per-share guidance excludes $0.37 per share of intangible asset amortization expense and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities. Excluding the potential impact of the transaction with Shire, the company is issuing diluted earnings-per-share guidance for the third-quarter 2014 of $0.77 to $0.79 on an adjusted basis, or $0.68 to $0.70 on a GAAP basis. The company's third-quarter adjusted diluted earnings-per-share excludes $0.09 per share of intangible asset amortization expense and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities. The company forecasting low to mid-single-digit operational sales growth in both the third of 2014. Gross margin ratio to be approximately 79%. For the fourth quarter, the company forecasting low to mid-single-digit operational sales growth. The gross margin ratio is expected to be somewhat lower than the third quarter, driven by product mix, particularly an increase in lower-margin Synagis sales.

AbbVie Inc. to Report Q2, 2014 Results on Jul 25, 2014

AbbVie Inc. announced that they will report Q2, 2014 results Pre-Market on Jul 25, 2014

AbbVie Inc., Q2 2014 Earnings Call, Jul 25, 2014

AbbVie Inc., Q2 2014 Earnings Call, Jul 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:FP €38.38 EUR 0.00

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.75 USD -0.18
Amgen Inc $123.31 USD +0.66
Bristol-Myers Squibb Co $51.01 USD +1.21
Eli Lilly & Co $62.77 USD -0.62
Novo Nordisk A/S kr256.50 DKK +2.50
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 20.8x
Price/Sales 4.5x
Price/Book 18.2x
Price/Cash Flow 20.5x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.